Merck
HomeWebinarsThe Viscosity Reduction Platform: Enabling Subcutaneous (subQ) Delivery

The Viscosity Reduction Platform: Enabling Subcutaneous (subQ) Delivery

Webinar

Subcutaneous (subQ) administration can improve patient convenience and reduce healthcare costs by avoiding the need for hospitalization. Yet in some cases, high protein concentrations make formulations far more viscous, prohibiting this route of administration. While viscosity can normally be reduced by using certain excipients, merely adding more and more of a single excipient may not bring sufficient improvement and can even compromise protein stability. We will introduce an excipient platform that makes it possible to combine excipients in ways that can reduce protein viscosity to a greater extent.

In this webinar, you will learn about:
• Challenges arising from high concentrated protein formulations
• The viscosity reduction platform: a portfolio of excipients to manage protein viscosity
• The impact of viscosity reducing excipient use on protein stability
• The impact of protein viscosity on syringability

Speakers

Tobias Rosenkranz, Ph.D.

Merck

Senior Manager, Biomolecule Formulation R&D

Tobias Rosenkranz heads the Biomolecule Formulation team in the Liquid Formulation R&D department in Darmstadt. His lab mainly focuses on formulation challenges arising in protein formulations, such as protein viscosity and aggregation. A biophysicist by training, he holds a PhD from the HHU Düsseldorf/Research Centre Jülich. Prior to joining the company in 2017, Tobias was a basic researcher at UIUC (US) and UNSW Australia.

Webinar Information

Pharmaceutical and biopharmaceutical manufacturing

  • Classical pharma manufacturing
  • Duration:1 hour

  • Language:English

  • Presented:October 7, 2021